



APR - 1 2004

Device Name:

Trade Name:

Stryker Interventional Pain RF Generator

Common Name:

Electrosurgical generator

Classification Name:

Generator, Lesion, RF: 21 CFR 882.4400, GXD

Device Sponsor:

Manufacturer:

Valley Forge Scientific 136 Green Tree Rd. P.O. Box 1179 Oaks, PA 2521567

Regulatory Class:

Class II

Summary of Safety and Effectiveness:

The Stryker Interventional Pain RF Generator, in combination with the Stryker RF Electrodes and Cannulae, is intended for coagulation of soft tissues in orthopedic, arthroscopic, spinal, and neurosurgical applications. Examples include, but are not limited to, Facette Denervation, Percutaneous Chordotomy/Dorsal Root Entry Zone (DREZ) Lesion, Trigeminus Neuralgia, and Rhizotomy.

The Stryker Interventional Pain RF Generator is equivalent in intended use, safety, and effectiveness to existing devices being marketed by Oratec, Radionics, Baylis, NeuroTherm, and Arthrocare.

The Stryker Interventional Pain RF Generator does not raise any new safety and efficacy concerns when compared to similar devices already legally marketed. Therefore, the Stryker Interventional Pain RF Generator is substantially equivalent to these existing devices.

Jerry Malis

President CEO

Dated: 3.31.0



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR - 1 2004

Mr. Jerry Malis President Valley Forge Scientific Corp. 136 Green Tree Road, Suite 100 Oaks, Pennsylvania 19456

Re: K032601

Trade/Device Name: Stryker Interventional Pain RF Generator

Regulation Number: 21 CFR 882,4400

Regulation Name: Radiofrequency lesion generator

Regulatory Class: II Product Code: GXD Dated: January 30, 2004 Received: February 3, 2004

Dear Mr. Malis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Miriam C. Provost W Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices
Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure



Indications for Use

P.O. 6ox 1179 Oaks, PA 19456

PHONE 610-666-7500 FAX 610-666 7565

510(k) Number:	K032601			
Device Name:	Stryker Interventional Pain RF Generator			
Indications For Use:	The Stryker Interventional Pain RF Generator, in combination with the Stryker RF Electrodes and Cannulae, is intended for coagulation of soft tissues in orthopedic, arthroscopic, spinal, and neurosurgical applications. Examples include, but are not limited to, Facette Denervation, Percutaneous Chordotomy/Dorsal Root Entry Zone (DREZ) Lesion, Trigeminus Neuralgia, Peripheral Neuralgia, and Rhizotomy.			
Prescription Use	AND/OR	Over-The- Counter U	se	
(Per 21 CFR 801 Subpart D)		(21 CFR 807 Subpart		
(PLEASE DO NOT WRITE B NEEDED)	ELOW THIS LINE-	CONTINUE ON ANOT	HER PAGE	IF
<u>Muran</u> (Division S Division of	e of CDRH, Office NOVOJ Sign-Off) General, Restological Devices		1 (ODE)	,,,, , , , , , , , , , , , , , , , , ,
	nber K 6324	60/	Page <u>1</u>	of <u>1</u> 136 Green Tree Road Suite 100 P.O. Box 1179

Simply the finest energy source available for surgery